Cord Blood America, Inc. (OTC:CBAI.ob), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it has purchased a minority interest in Stem Cells VIDAPLUS, a Spanish-owned company which preserves umbilical cord stem cells at the Institute of Transfusion [...]
{ 0 comments }
Cord Blood America, Inc. (OTC:CBAI.ob), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced yesterday that Matthew Schissler, CEO and co-founder, explains in detail the plans for the Company’s recapitalization in a ten-minute interview. The video and text of the [...]
{ 0 comments }
According to pharmaceutical research firm IMS Health, U.S. sales of oncology drugs increased only 3.5 percent in the first nine months of 2010, compared to sales growth of 23 percent in 2006, 14 percent in 2007, and 9 percent in 2008 and 2009. The slowdown in sales growth is primarily being caused by price increases [...]
{ 0 comments }
LAS VEGAS, Nov. 8, 2010 — Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC:CBAI.ob), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, is pleased to announce that it is the first cord blood stem cell storage company to become an alliance partner [...]
{ 0 comments }
1.) As of today, there are now 158.1M + 35.7M = 193.8M shares outstanding, with today adding 22.6% more dilution … its now basically doubled over the course of the past year!!! 2.) The Liquid Surfaxin is the Lead Program, and it is targeted to a $75M/yr U.S.-only market opportunity, which is currently served by [...]
{ 0 comments }
Let’s look into brief profile of CYCC. Cyclacel Pharmaceuticals, Inc has various drugs under develipment: they are: Sapacitabine (CYC682): An oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies, , such as acute myeloid leukemia in the elderly, myelodysplastic syndromes, cutaneous T-cell lymphoma, and lung cancer. Seliciclib (CYC202): A [...]
{ 0 comments }
On Januvary 22 nd Cord Blood America started another chapter by opening a Office and Lab atLas Vegas. Here is the video of the event. Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is [...]
{ 2 comments }
BEIJING, Nov. 17 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA – News), a leading developer and provider of vaccines in China, announced today that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company’s H1N1 vaccine. The population has been expanded to include people over 60 years old. The [...]
{ 1 comment }
BioElectronics, the makers of inexpensive Drug Free, Anti-inflammatory Medical Devices and Patches. Recently chosen as “One of 9 Medical Breakthroughs That May Change Your Life.” Approved for sale in over 20 Countries including Canada, Italy, India and Korea. Producers of two product lines, Actipatch for retail sales and RecoveryRx for medical sales. BioElectronics Corp. (PINKSHEETS: [...]
{ 1 comment }
The business of curing diseases can be a lucrative one, and investors will jump on the bandwagon for any stock that shows the promise of a big breakthrough. Biotechnology stocks are great for long-term investment. Biotechnology is trading on big discounts to the market now. That’s one good reason why we think now is a [...]
{ 1 comment }